Pre-Treatment Risk Factors for EV-Induced Peripheral Neuropathy in aUC: Analysis of the UNITE Study

At the ESMO Congress 2024, Karine Tawagi, MD, of University of Illinois, and Amanda Nizam, MD, of Cleveland Clinic, break down the UNITE study hypothesized pre-treatment clinical factors that were thought to be associated with increased risk for enfortumab vedotin-induced peripheral neuropathy, as well as the multivariable logistic regression model that identified the pre-treatment factors associated with this higher risk.

They then stress the need for closer monitoring and earlier intervention to mitigate this adverse event in certain patients beginning treatment with enfortumab vedotin, including those with higher albumin and prior neuropathy.